Journal article

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes

Lennox Din, Mohammad Sheikh, Nikitha Kosaraju, Karin Ekstrom Smedby, Sasha Bernatsky, Sonja Berndt, Christine F Skibola, Alexandra Nieters, Sophia Wang, James D McKay, Pierluigi Cocco, Marc Maynadie, Lenka Foretova, Anthony Staines, Thomas M Mack, Silvia de Sanjose, Timothy J Vyse, Leonid Padyukov, Alain Monnereau, Alan A Arslan Show all

GENETIC EPIDEMIOLOGY | WILEY | Published : 2019

Abstract

Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) po..

View full abstract

Grants

Awarded by HCI Comprehensive Cancer Center Support grant


Awarded by PIA Investissmeent d'avenir RHU programme KTD Innov


Awarded by Karolinska Institutet Distinguished Professor Award


Awarded by National Institutes of Health


Awarded by NIH


Awarded by grant MH CZ -DRO


Awarded by National Cancer Institute SEER Program


Awarded by MH CZ -DRO


Awarded by European Commission


Awarded by Spanish Ministry of Economy and Competitiveness-Carlos III Institute of Health - FEDER funds/European Regional Develpment Fund (ERDF)-a way to build Europe


Awarded by Marato de TV3 Foundation


Awarded by Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)


Awarded by CERCA Programme/Generalitat de Catalunya


Awarded by Federal Office for Radiation Protection grants


Awarded by Jose Carreras Leukemia Foundation


Awarded by German Federal Ministry for Education and Research


Awarded by National Center for Advancing Translational Science


Awarded by Wellcome Trust


Awarded by US National Multiple Sclerosis Society


Awarded by Neuropromise EU grant


Awarded by Italian Foundation for Multiple Sclerosis


Awarded by Spanish Ministry of Health


Awarded by HYPERGENES


Awarded by NCI Specialized Programs of Research Excellence (SPORE) in Human Cancer


Awarded by National Cancer Institute


Awarded by Italian Ministry for Education, University and Research


Awarded by Italian Association for Cancer Research


Awarded by Regional Administration of Sardinia


Awarded by Institut National du Cancer


Awarded by Australian National Health and Medical Research Council


Awarded by Lymphoma Foundation


Awarded by Lymphoma Research Fund


Awarded by Robert and Kate Niehaus Clinical Cancer Genetics Research Initiative


Awarded by National Natural Science Foundation of China


Awarded by National Institute of Environmental Health Sciences


Awarded by NIH/NHLBI


Awarded by GENEVA Coordinating Center


Awarded by Stockholm Country Council


Awarded by Lundbeck Foundation


Awarded by Danish Cancer Society


Awarded by National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services



Funding Acknowledgements

Partial support for all datasets within the UPDB is provided by the Huntsman Cancer Institute (HCI) and the HCI Comprehensive Cancer Center Support grant, Grant/Award Number: P30 CA42014; Pierre-Antoine Gourraud is currently supported by the ATIP-Avenir INSERM program and the Region Pays de Loire ConnecTalent, ARSEP Foundation (Fondation pour l'Aide a la recherche sur la Sclerose En Plaques Foundation", the Nantes University Foundation, the PIA Investissmeent d'avenir RHU programme KTD Innov, Grant/Award Number: H2020 EU-TRAIN; Hans-Olov Adami is supported by the Karolinska Institutet Distinguished Professor Award, Grant/Award Number: Dnr: 2368/10-221; Karin E Smedby is supported by the Swedish Cancer Society, the Strategic Research Program in Epidemiology at Karolinska Institute and National Institutes of Health, Grant/Award Number: (2009/659) and (5R01 CA69669-02); Nicola Camp reports support from, Grant/Award Number: NIH R01CA134674; John J Spinelli and Angela R Brooks-Wilson report support from the Canadian Institutes for Health Research (CIHR); the Canadian Cancer Society; and the Michael Smith Foundation for Health Research, Grant/Award Number: na; The UCR is supported in part by NIH contract, Grant/Award Number: HHSN261201000026C; James R Cerhan is supported by NIH grants, Grant/Award Number: R01 CA92153, R01 CA200703, P50 CA97274, U01 CA195568; Lenka Foretova is supported by a grant MH CZ -DRO, Grant/Award Number: (MMCI, 00209805); David Conti is supported by the following NIH, Grant/Award Numbers: P01CA196569, R01CA201407, R01CA206019, 5P30CA014089; Karolinska Institutet Distinguished Professor Award; NIH, Grant/Award Numbers: R01CA134674, NO1-CO-12400; Huntsman Cancer Institute (HCI) and the HCI Comprehensive Cancer Center Support grant, Grant/Award Number: P30 CA42014; National Cancer Institute SEER Program, Grant/Award Number: HHSN261201000026C; MH CZ -DRO, Grant/Award Number: 00209805; Swedish Cancer Society; Strategic Research Program in Epidemiology at Karolinska Institute and National Institutes of Health, Grant/Award Number: 5R01 CA69669-02; European Commission, Grant/Award Numbers: QLK4-CT-2000-00422, FOODCT-2006-; Spanish Ministry of Economy and Competitiveness-Carlos III Institute of Health cofunded by FEDER funds/European Regional Develpment Fund (ERDF)-a way to build Europe, Grant/Award Numbers: CIBERESP, PI11/01810, RCESP C03/09, RTICESP C03/10, RD06/0020/0095, PI17/01280, PI14/01219; Marato de TV3 Foundation, Grant/Award Number: 051210; Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), CERCA Programme/Generalitat de Catalunya for Institutional Support, Grant/Award Numbers: 2014SRG756, 2017SGR1085, 2009SGR1465; Federal Office for Radiation Protection grants, Grant/Award Number: StSch4261 and StSch4420; Jose Carreras Leukemia Foundation grant, Grant/Award Number: DJCLS-R12/23; German Federal Ministry for Education and Research, Grant/Award Number: BMBF-01-EO-; National Institutes of Health, Grant/Award Numbers: CA118444, CA148690, CA92153, K08CA134919, AI076544, NS032830, NS049477, NS19142, NS049510, NS26799, NS43559, NS067305, CA104021, RR020092, RR024992 and K23N/S048869, CA97274, R01 CA92153, CA186107, CA87969, CA49449, CA149445, CA098122, and CA134958; National Center for Advancing Translational Science, Grant/Award Number: UL1 TR000135; Wellcome Trust, Grant/Award Number: 085475/B/08/Z, 085475/Z/08/Z, 075491/Z/04/Z, and 068545/Z/02; US National Multiple Sclerosis Society, Grant/Award Number: RG 4201-A-1; Neuropromise EU grant, Grant/Award Number: LSHM-CT-; Italian Foundation for Multiple Sclerosis, Grant/Award Number: 2002/R/40, 2005/R/10, 2008/R/11, and 2008; Association of British Neurologists, Spanish Ministry of Health, Grant/Award Number: FISPI060117; HYPERGENES, Grant/Award Number: HEALTH-F4-the German Ministry of Education and Research, the Helmholtz Zentrum Munchen-National Research Center, the German National Genome Research Network (NGFN), the LMUinnovativ, the Knut and Alice Wallenberg Foundation, the Center for Applied Genomics from the Children's Hospital of Philadelphia Development Award, the Agency for Science & Technology and Research of Singapore, and the Susan G. Komen Breast Cancer Foundation. NCI Specialized Programs of Research Excellence (SPORE) in Human Cancer (P50 CA97274); National Cancer Institute, Grant/Award Number: P30 CA086862, P30 CA15083; Italian Ministry for Education, University and Research, Grant/Award Number: PRIN 2007 prot.2007WEJLZB, PRIN 2009 prot. 20092ZELR2; Italian Association for Cancer Research, Grant/Award Number: 11855; Regional Administration of Sardinia, Grant/Award Number: LR7 CRP59812/2012; Institut National du Cancer, Grant/Award Number: 2008-020; National Center for Advancing Translational Science, Grant/Award Number: UL1 TR000135; National Cancer Institute, Grant/Award Number: P30 CA015083; Australian National Health and Medical Research Council grants, Grant/Award Numbers: 209057, 251553, 504711, 396414, ID990920; Lymphoma Foundation, Grant/Award Number: LF5541; Lymphoma Research Fund, Grant/Award Number: 74419; Robert and Kate Niehaus Clinical Cancer Genetics Research Initiative, Grant/Award Number: 57470; National Natural Science Foundation of China, Grant/Award Number: 61471078; National Cancer Institute, Grant/Award Number: R01 CA098661, P30 CA016087; National Institute of Environmental Health Sciences, Grant/Award Number: ES000260; NIH/NHLBI, Grant/Award Number: R37HL039693; GENEVA Coordinating Center, Grant/Award Number: U01 HG004446; Stockholm Country Council, Grant/Award Number: 20110229; Lundbeck Foundation Grant, Grant/Award Number: R19-A2364; Danish Cancer Society Grant, Grant/Award Number: DP 08-155; National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts, Grant/Award Number: HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C; National Cancer Institute, Grant/Award Number: CA62006